News

Discover key insights from leading ophthalmology experts at the AAO meeting, featuring presentations, posters, and innovative discussions from October 17-20.

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP)

Additionally, the company also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Holz discusses advancements in retinal disease treatments at the EURETINA meeting, featuring gene therapy and innovative implants to enhance patient care.

A study reveals diverse ocular symptoms in Sjögren’s disease, linking eye features to oral and pain manifestations for personalized treatment strategies.

A recent study reveals that most UK patients with geographic atrophy find intravitreal complement inhibitors acceptable, emphasizing the importance of perceived visual benefits.

Vizz is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

Lupin notes that the acquisition will help to strengthen the company by “integrating VISUfarma’s established commercial operations.”

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

Patricio Schlottmann highlights promising long-term results of faricimab for wet AMD, showcasing sustained visual gains and excellent safety in patients.

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

A study reveals atropine induces less myopic refraction than cyclopentolate in preschoolers, impacting premyopia diagnosis and intervention strategies.

Additionally, the company plans to perform cash-saving actions, including a workforce reduction.

Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with comprehensive data and insights for better patient care.

Explore how digital image management and AI transform ophthalmology, enhancing diagnostics and personalizing patient care in retina practices.

Subramanian discusses how subtle retinal and optic nerve findings can point to underlying neurologic disease.

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

This new technology, the MacuMira system, is a non-invasive treatment now available in more than 150 clinics across Canada.

Residents across ophthalmology, optometry, and retina care were recognized for leadership, research, and dedication to advancing patient care.

Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.

Considering rapid increases in myopia, authors conducted a longitudinal cohort study of twins and their parents with the goal of exploring the intergenerational changes in the myopia epidemic in China.